When is it appropriate to discontinue statin therapy in a patient with a history of venous or arterial thromboembolism?

When to Stop Statins in Patients with History of Blood Clots

A history of blood clots (venous or arterial thromboembolism) is NOT an indication to discontinue statin therapy—in fact, statins should generally be continued or even initiated in these patients due to cardiovascular benefits and emerging evidence of reduced VTE recurrence risk.

Key Clinical Principle

The question appears to conflate two separate issues: statins are primarily prescribed for atherosclerotic cardiovascular disease (ASCVD) prevention, not for blood clot history. However, recent evidence suggests statins may actually reduce recurrent VTE risk 1, 2.

When Statins SHOULD Be Stopped

Based on ACC/AHA guidelines 3, discontinue statins only for these specific reasons:

Immediate Discontinuation Required:

• Severe unexplained muscle symptoms or fatigue - promptly stop and evaluate for rhabdomyolysis (check CK, creatinine, urinalysis for myoglobinuria) 3
• Signs of hepatotoxicity - unusual fatigue/weakness, loss of appetite, abdominal pain, dark urine, jaundice 3
• Documented contraindications (not related to blood clot history)

Temporary Discontinuation for Evaluation:

• Mild-to-moderate muscle symptoms - stop until symptoms can be evaluated, rule out other causes (hypothyroidism, renal/hepatic dysfunction, vitamin D deficiency, rheumatologic disorders), then rechallenge 3

Consider Discontinuation in Poor Health Status:

According to recent guideline reviews 4, it may be reasonable to consider stopping statins in patients with:

• Limited life expectancy (<3 years)
• Significant functional decline or frailty
• Multimorbidity where harm outweighs benefit

Special Considerations for Patients with Blood Clot History

Arterial Thromboembolism (MI, Stroke, PAD):

• Continue high-intensity statin therapy if age ≤75 years 5
• Continue moderate-to-high intensity statin if age >75 years after evaluating frailty, drug interactions, and patient preferences 5
• Never discontinue after acute events - stopping statins after acute MI or stroke is associated with worse outcomes and increased mortality compared to never being on statins 6

Venous Thromboembolism (DVT, PE):

• Do NOT stop statins - emerging evidence shows statins reduce recurrent VTE risk by approximately 25-30% 2, 7
• Statins appear safe when combined with anticoagulation without increasing major bleeding risk 7
• The protective effect applies to both recurrent PE (RR 0.75) and DVT (RR 0.66) 2

Critical Pitfalls to Avoid

1. Do not confuse VTE with statin side effects - blood clots are not caused by statins and are not a reason to stop them
2. Do not discontinue statins perioperatively unless absolutely necessary for surgery 8
3. Avoid unnecessary discontinuation - establish baseline muscle symptoms before starting therapy to distinguish pre-existing from statin-related symptoms 3
4. After acute vascular events, continuation is crucial - there may be a "rebound phenomenon" with worse outcomes if stopped 6

Algorithm for Rechallenge After Muscle Symptoms

If muscle symptoms resolve after stopping 3:

1. Rechallenge with original or lower dose of same statin
2. If symptoms recur (causal relationship confirmed), switch to low-dose different statin
3. Gradually uptitrate as tolerated
4. If symptoms persist after 2 months off statins, investigate other causes
5. If symptoms unrelated to statin, resume original dose

Bottom Line

Blood clot history—whether venous or arterial—is not a reason to stop statins. The only valid reasons for discontinuation are statin-specific adverse effects (severe myopathy, hepatotoxicity), absolute contraindications, or poor overall health status where life expectancy is very limited. In patients with ASCVD (arterial events), statins are Class I indicated and should not be stopped 5. In patients with VTE, emerging evidence suggests statins provide additional protection against recurrence when combined with anticoagulation 1, 2.